Pfizer (PFE) PT Lowered to $36 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
JPMorgan analyst Chris Schott lowered the price target on Pfizer (NYSE: PFE) to $36.00 (from $37.00) while maintaining a Neutral rating.
The analyst comments "We see a clear inflection in growth for Pfizer after the Lyrica patent expiration in 2019 with a reacceleration of the company’s organic top- and bottom-line growth in the 2020-2025 period (top-line growth of ~5% expected to be above Major Pharma). However, we remain Neutral with valuation reflecting visible near-term growth and another major patent cycle post-2025."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Honeywell International (HON) PT Lowered to $261 at BMO Capital
- Third Coast Bancshares Inc (TCBX) PT Lowered to $54 at StoneX
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
